Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with Rituximab in relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL)

Next Previous
Search
Trial Profile

A Phase I/II study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with Rituximab in relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL)

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 12 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bifikafusp alfa (Primary) ; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Philogen

    • Most Recent Events

    • 06 Oct 2023 Status changed from active, no longer recruiting to discontinued. Slow progression due to difficulties in finding eligible patients. Competitive clinical trials with innovative agents and new approved products lead definitive stop.
    • 06 Oct 2023 This study has been discontinued in Germany, according to European Clinical Trials Database record.
    • 19 Apr 2022 Planned End Date changed from 1 Dec 2019 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top